Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Key Highlights
- ➤Libtayo reduced death risk 37% after 44 months, versus 22% at 30 months
- ➤88% of recurrent placebo patients received subsequent Libtayo after crossover
- ➤Adjuvant Libtayo improved DFS in MRD-negative patients, HR 0.45
- ➤Adjuvant Libtayo improved DFS in MRD-positive patients, HR 0.24
- ➤Grade ≥3 adverse events occurred in 26% with Libtayo versus 17% placebo
Expert Statements
Danny Rischin, M.D., M.B.B.S., F.R.A.C.P.; Research Lead, Head and Neck Cancer and Cutaneous SCC, Department of Medical Oncology, Peter MacCallum Cancer Centre
“As the Phase 3 C-POST trial data continue to mature, we are seeing an evolving and clinically meaningful overall survival benefit with adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma, as well as sustained disease-free survival benefit regardless of whether minimal residual disease is detectable at baseline.”
Danny Rischin, M.D., M.B.B.S., F.R.A.C.P.; Research Lead, Head and Neck Cancer and Cutaneous SCC, Department of Medical Oncology, Peter MacCallum Cancer Centre
“These data provide compelling evidence of the long-term, durable benefit of adjuvant treatment with Libtayo in high-risk CSCC after surgery and radiation, further supporting Libtayo as a transformative standard of care for these patients.”
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence
New prospective analyses confirm sustained disease-free survival (DFS) benefit with adjuvant Libtayo, including in patients who are minimal residual disease (MRD) negative at baseline
Get started
Create a free account to read the full story.